Q1 EPS Estimate for Arcus Biosciences Reduced by Analyst

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings estimates for shares of Arcus Biosciences in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings of ($1.13) per share for the quarter, down from their previous forecast of ($0.89). The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.41) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($1.72) EPS and FY2028 earnings at $1.06 EPS.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business had revenue of $36.00 million for the quarter, compared to analysts’ expectations of $29.38 million.

Other equities analysts have also recently issued reports about the stock. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $24.00 in a report on Wednesday. Finally, Bank of America decreased their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and an average price target of $30.25.

Arcus Biosciences Trading Up 10.2 %

Arcus Biosciences stock opened at $10.89 on Friday. The company’s fifty day simple moving average is $13.37 and its 200-day simple moving average is $15.40. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences has a 12 month low of $9.85 and a 12 month high of $20.00. The stock has a market cap of $1.14 billion, a P/E ratio of -3.46 and a beta of 0.84.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RCUS. GSA Capital Partners LLP raised its position in shares of Arcus Biosciences by 17.8% during the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock valued at $2,866,000 after buying an additional 28,307 shares during the last quarter. Quest Partners LLC raised its position in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after buying an additional 186,750 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Arcus Biosciences during the third quarter valued at about $244,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock valued at $1,237,000 after buying an additional 22,716 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insiders Place Their Bets

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, with a total value of $201,200.00. Following the transaction, the director now owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.